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lished studies, only 25 studies were included. The major-
ity of the studies was cost-effectiveness analysis (68%).
The common weaknesses included the use of non-
incremental analyses (68%, 17/25), lack of question
clearly stated (36%, 9/25), and an absence of perspective
explicitly stated (36%, 9/25). Provider perspective was
used most frequently (48%, 12/25). Only six studies
properly identiﬁed, measured, and valued all relevant cost
and consequences of the interventions studied. Out of 6
studies which required differential timing adjustment,
83% (5/6) discounted both cost and consequences. Only
8 studies (32%) properly performed sensitivity analyses.
Our ﬁndings found no study meeting all criteria of Drum-
mond’s 10-item checklist. CONCLUSIONS: Overall, the
quality of economic evaluation studies in Thailand is still
poor. This study indicates the urgent needs to improve the
standard of economic evaluation studies in Thailand.
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OBJECTIVES: The Regie de l’assurance maladie du
Quebec (RAMQ), an administrative database containing
medical and pharmaceutical services records, is frequently
used in epidemiologic and economic studies. In-hospital
length of stay (LOS) and readmissions are important com-
ponents of such studies and can be estimated through a
linkage between RAMQ and MED-ECHO (hospital sep-
aration records) databases with high reliability. However,
this linkage is cumbersome and time-consuming. These
parameters can also be estimated directly from RAMQ
medical services database. Unfortunately, the data con-
cerning hospitalizations are not speciﬁcally contained in
RAMQ and must be deduced from in-hospital medical
procedures, claimed by the physician. The objective of
this study was to develop and to validate an analytical
algorithm to estimate LOS and readmissions in a target
population using RAMQ claims database. METHODS:
Using the RAMQ medical services database, we identiﬁed
1441 patients aged ≥65 years with hospitalization
records, who were treated for chronic obstructive pul-
monary disease (COPD) between 1989 and 1996. In-
hospital claims were identiﬁed using institutional coding.
The validation process was then implemented through
comparison analyses with a “gold standard”, MED-
ECHO database, using deterministic linkage method.
RESULTS: According to the RAMQ, 1233/1441 patients
were admitted at least once during the study period. Com-
pared to MED-ECHO, the sensitivity and speciﬁcity of
the algorithm identifying the ﬁrst in-hospital stay (1174
cases) were 97% and 75%, respectively, with x = 0.76.
The mean LOS was 12.1 days, with a geometric mean of
6.2 days in RAMQ vs. 13.5 and 6.7 days (p < 0.001) in 
MED-ECHO; the average readmission was 3.7 times vs.
3.8 (p = 0.36) for the entire cohort, respectively. CON-
CLUSIONS: The algorithm is able to predict in-hospital
LOS and readmissions with slight underestimation. 
Substantial time and cost savings can be made through
estimation of in-hospital stays using RAMQ database.
This algorithm is yet to be validated for other medical
conditions.
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OBJECTIVES: Patient characteristics (age, sex, smoking
status, baseline FEV-1 percent predicted) can have impor-
tant consequences for the prognosis of Chronic Obstruc-
tive Pulmonary Disease (COPD). A Markov model for
COPD was developed that allowed different patient prog-
noses and consideration was given to how such patient
heterogeneity be analysed and presented. METHODS: A
four state Markov model of COPD progression (mild,
moderate, severe COPD and a dead state) was structured
using the American Thoracic Society’s FEV-1 thresholds
for the deﬁnition of disease. Time to progression through
the states was modeled as a function of age, sex, baseline
FEV-1 and smoking status. Frequency of disease exacer-
bations was modeled as a function of the disease state.
Utility values for the health states were taken from the
literature and costs were estimated from the literature and
expert opinion. Treatment effects were estimated from
emerging clinical trial data. Lifetime cost and QALY out-
comes were predicted from the model for 2068 subjects
for whom information on prognostic factors was avail-
able. RESULTS: Evaluating the model at the mean of the
prognostic factors for the population of interest gave
costs of $41,000 and $66,000 for the control and treat-
ment groups. The corresponding QALY estimates were
2.6 and 3.5 leading to an estimated ICER of $27,000 per
QALY gained. However, averaging across the 2068 indi-
vidual estimates yielded $43,000 and $72,000 for costs
and 3.7 and 4.6 for QALYs in the control and treatment
groups respectively, generating an ICER estimate of
$32,000 per QALY. CONCLUSIONS: These results
clearly demonstrate how, in the presence of heterogene-
ity, evaluating models at the average values of important
prognostic factors can lead to serious bias compared to
averaging over individual-based predictions. This bias 
is due to the non-linearities inherent in most Markov
models and is exacerbated once uncertainty in parameter
estimation is included in a fully probabilistic framework.
